{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T03:38:01Z","timestamp":1792208281138,"version":"4.4.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.jtha.2024.01.018","type":"journal-article","created":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T06:33:53Z","timestamp":1711089233000},"page":"922-925","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Lower-dose emicizumab prophylaxis: can less be more?"],"prefix":"10.1016","volume":"22","author":[{"given":"Alok","family":"Srivastava","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Iorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2024.01.018_bib1","doi-asserted-by":"crossref","first-page":"633","DOI":"10.2165\/11535960-000000000-00000","article-title":"Population pharmacokinetics of therapeutic monoclonal antibodies","volume":"49","author":"Dirks","year":"2010","journal-title":"Clin Pharmacokinet Cham"},{"key":"10.1016\/j.jtha.2024.01.018_bib2","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/hae.14292","article-title":"Pharmacokinetic implications of dosing emicizumab based on vial size: a simulation study","volume":"27","author":"Yu","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.01.018_bib3","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1055\/s-0040-1717114","article-title":"Pharmacokinetics and pharmacodynamics of emicizumab in persons with hemophilia A with factor VIII inhibitors: HAVEN 1 study","volume":"121","author":"Schmitt","year":"2021","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.01.018_bib4","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/hae.14359","article-title":"Determining the approximate factor VIII level of patients with severe haemophilia A on emicizumab using in\u00a0vivo global haemostasis assays","volume":"27","author":"Kizilocak","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.01.018_bib5","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1007\/s40262-020-00904-z","article-title":"Population pharmacokinetic analysis and exploratory exposure\u2013bleeding rate relationship of emicizumab in adult and pediatric persons with hemophilia A","volume":"59","author":"Retout","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jtha.2024.01.018_bib6","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/hae.13953","article-title":"Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: final results from the ASPIRE extension study","volume":"26","author":"Nolan","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.01.018_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.100074","article-title":"The efficacy of the entire-vial dosing of emicizumab: real-world evidence on plasma concentrations, bleeds, and drug waste","volume":"7","author":"Donners","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.01.018_bib8","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1055\/a-1499-0030","article-title":"Emicizumab dosing in children and adults with hemophilia A: simulating a user-friendly and cost-efficient regimen","volume":"122","author":"Bukkems","year":"2022","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.01.018_bib9","first-page":"47","article-title":"Optimizing maintenance dosing of emicizumab-kxwh as prophylaxis in hemophilia A: dosing to product labeling while minimizing drug waste","volume":"29","author":"Albini","year":"2023","journal-title":"J\u00a0Manag Care Spec Pharm"},{"key":"10.1016\/j.jtha.2024.01.018_bib10","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1111\/hae.14483","article-title":"Do we need all that emicizumab?","volume":"28","author":"Lehtinen","year":"2022","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.01.018_bib11","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/hae.14785","article-title":"Low dose emicizumab prophylaxis in haemophilia a patients: a pilot study from India","volume":"29","author":"Bansal","year":"2023","journal-title":"Haemophilia"},{"issue":"Suppl\u00a02","key":"10.1016\/j.jtha.2024.01.018_bib12","article-title":"Efficacy of reduced-dose emicizumab in haemophilia A with inhibitors: real world experience in\u00a0East Malaysia [abstract]","volume":"5","author":"Tang","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.01.018_bib13","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/hae.14707","article-title":"Effectiveness of monthly low dose emicizumab prophylaxis without 4-week loading doses among patients with haemophilia A with and without inhibitors: a case series report","volume":"29","author":"Chuansumrit","year":"2023","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.01.018_bib14","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.jtha.2023.12.023","article-title":"Low-dose emicizumab prophylaxis in severe haemophilia A patients-a retrospective study bringing new hope for our patients","volume":"22","author":"Patil","year":"2024","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.01.018_bib15","first-page":"1","article-title":"Response to standard vs low dose emicizumab in inhibitor positive hemophilia A","volume":"37","author":"Radhakrisjnan","year":"2021","journal-title":"Indian J Hematol Blood Transfus"},{"key":"10.1016\/j.jtha.2024.01.018_bib16","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1056\/NEJMoa1511769","article-title":"Factor VIII\u2013mimetic function of humanized bispecific antibody in hemophilia A","volume":"374","author":"Shima","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.01.018_bib17","doi-asserted-by":"crossref","unstructured":"Seth T, John MJ, Chakrabarti P, Shanmukhaiah C, Verma SP, Radhakrishnan N, Dolai TK. Cost-effectiveness analysis of emicizumab prophylaxis in patients with haemophilia A in India. Haemophilia 2023; in press. https:\/\/doi.org\/10.1111\/hae.14921","DOI":"10.1111\/hae.14921"},{"key":"10.1016\/j.jtha.2024.01.018_bib18","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1182\/bloodadvances.2018020552","article-title":"The frequency of joint hemorrhages and procedures in nonsevere hemophilia A vs B","volume":"2","author":"Soucie","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2024.01.018_bib19","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s40262-021-01042-w","article-title":"Pharmacokinetics and associated efficacy of emicizumab in humans: a systematic review","volume":"60","author":"Donners","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jtha.2024.01.018_bib20","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/hae.13616","article-title":"Treatment regimens and outcomes in severe and moderate haemophilia A in the UK: the THUNDER study","volume":"25","author":"Scott","year":"2019","journal-title":"Haemophilia"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153878362400059X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153878362400059X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:40:23Z","timestamp":1761536423000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S153878362400059X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S153878362400059X"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2024.01.018","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lower-dose emicizumab prophylaxis: can less be more?","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2024.01.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}